One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the American Heart Association"
DOI: 10.1161/jaha.121.023454
Abstract: Background It is unknown whether contemporary drug-eluting stents have a similar safety profile in high bleeding risk patients treated with 1-month dual antiplatelet therapy following percutaneous coronary interventions. Methods and Results We performed an interventional,… read more here.
Keywords: bleeding risk; high bleeding; month; month dual ... See more keywords